Immune checkpoint inhibitors as first-line and salvage therapy for advanced non-small-cell lung cancer

Future Oncology

Volumn 12, Issue 15, 2016, Pages 1805-1822

  Decatris, Marios P ^a   O'Byrne, Kenneth J ^b  

^a CHELTENHAM GENERAL HOSPITAL   (United Kingdom)

^b QUEENSLAND UNIVERSITY OF TECHNOLOGY   (Australia)

Author keywords

checkpoint inhibitors; first line therapy; immunotherapy; non small cell lung cancer; salvage therapy

Indexed keywords

ANTINEOPLASTIC AGENT; ATEZOLIZUMAB; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DOCETAXEL; DURVALUMAB; IMMUNE CHECKPOINT INHIBITOR; IPILIMUMAB; NIVOLUMAB; PEMBROLIZUMAB; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 RECEPTOR; PROTEIN TYROSINE KINASE INHIBITOR; TICILIMUMAB; UNCLASSIFIED DRUG; MONOCLONAL ANTIBODY;

ADVANCED CANCER; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RECURRENCE; DRUG APPROVAL; DRUG RESPONSE; DRUG TREATMENT FAILURE; HISTOPATHOLOGY; HUMAN; MELANOMA; MOLECULARLY TARGETED THERAPY; MONOTHERAPY; NON SMALL CELL LUNG CANCER; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHASE 4 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SALVAGE THERAPY; SQUAMOUS CELL CARCINOMA; UNSPECIFIED SIDE EFFECT; CARCINOMA, NON-SMALL-CELL LUNG; IMMUNOTHERAPY; LUNG NEOPLASMS; PROCEDURES;

ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; HUMANS; IMMUNOTHERAPY; LUNG NEOPLASMS; SALVAGE THERAPY;

EID: 84979747908     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon-2016-0086     Document Type: Article

References (93)

1. Torre LA, Bray F, Siegel RL et al. Global cancer statistics, 2012. CA Cancer J. Clin. 65, 87-108 (2015)
2. DeAngelis R, Sant M, Coleman MP et al. Cancer survival in Europe 1999-2007 by country and age: results of EUROCARE-5-a population-based study. Lancet Oncol. 15, 23-34 (2014)
3. Cooley WB. May 1893. The treatment of malignant tumours by repeated inoculations of erysipelas: with a report of ten original cases. Am. J. Med. Sci. 105, 487-511 (1893)
4. Grulich AE, van Leeuwen MT, Falster MO, Vajdic CM. incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis. Lancet 370, 59-67 (2007)
5. Thomas JA, Baldini M. The role of innate immunity in spontaneous regression of cancer. Indian J. Cancer 48, 246-251 (2011)
6. Jonasch E, Halusdka FG. Interefron in oncological practice: review of interferon biology, clinical applications and toxicities. Oncologist 6, 34-55 (2001)
7. Decatris M, Santhanam S, O'Byrne K. Potential of interferon-alpha in solid tumours: part 1. Biodrugs 16(4), 261-281 (2002)
8. Kirkwood JM, Tarhini AA. Biomarkers of therapeutic response in melanoma and renal cell carcinoma. Potential inroads to improved immunotherapy. J. Clin. Oncol. 27, 2583-2585 (2009)
9. Pennell NA. Understanding the rationale for immunotherapy in non-small cell lung cancer. Semin. Oncol. 42(5 Suppl. 2), S3-S10 (2015)
10. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat. Rev. Cancer. 12(4), 252-264 (2012)
11. Vansteenkiste J. Immunotherapy for non-small cell lung cancer: the past 10 years. Future Oncol. 11(19), 2681-2695 (2015)
12. Waterhouse P, Penninger JM, Timms E et al. Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4. Science 270, 985-988 (1995)
13. Tivol EA, Boriello F, Schweitzer AN, Lynch WP, Bluestone JA, Sharpe AH. Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity 3, 541-547 (1995)
14. Leach DR, Krummel MF, Allison JP. Enhancement of antitumor immunity by CTLA-4 blockade. Science 271, 1734-1736 (1996)
15. Hodi FS, O'Day SJ, McDermott DF et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363(8), 711-723 (2010)
16. Robert C, Thomas L, Bondarenko I et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N. Engl. J. Med. 364(26), 2517-2526 (2011)
17. Lynch TJ, Bondarenko I, Luft A et al. Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small cell lung cancer: results from a randomized double-blind, multicentre Phase II study. J. Clin. Oncol. 30(17), 2046-2054 (2012)
18. Spigel DR, Reckamp KL, Rizvi NA et al. A Phase III study (CheckMate017) of nivolumab (NIVO); anti-programmed death-1 (PD-1) vs docetaxel (DOC) in previously treated advanced or metastatic squamous (SQ) cell non-small cell lung cancer (NSCLC). J. Clin. Oncol. 33(Suppl. 15), Abstract 8009 (2015)
19. Brahmer J, Reckamp KL, Baas P et al. Nivolumab versus docetaxel in advanced squamous cell non-small cell lung cancer. N. Engl. J. Med. 373(2), 123-135 (2015)
20. Paz-Ares L, Horn L, Borghaei H et al. Phase III, randomized trial (CheckMate 057) of nivolumab (NIVO) versus docetaxel (DOC) in advanced non-squamous (non-SQ) non-small cell lung cancer (NSCLC). J. Clin. Oncol. 33(Suppl. 15), LBA109 (2015)
21. Borghaei H, Paz-Ares L, Horn L et al. Nivolumab versus docetaxel in advanced non-squamous non-small cell lung cancer. N. Engl. J. Med. 373(17), 1627-1639 (2015)
22. Bustamante Alvarez JG, Gonzalez-Cao M, Karachaliou N et al. Advances in immunotherapy for treatment of lung cancer. Cancer Biol. Med. 12(3), 209-222 (2015)
23. ClinicalTrials.gov: Phase 3 trial in squamous non-small cell lung cancer subjects comparing ipilimumab plus paclitaxel and carboplatin versus placebo plus paclitaxel and carboplatin. https://clinicaltrials.gov
24. Zatloukal P, Heo DS, Park K et al. Randomized Phase II clinical trial comparing tremelimumab (CP-675,206) with best supportive care (BSC) following first-line platinum-based therapy in patients (pts) with advanced non-small cell lung cancer (NSCLC). J. Clin. Oncol. 27(Suppl. 15), Abstract 8079 (2009)
25. ClinicalTrials.gov: a global study to assess the effects of MEDI4736, given as monotherapy or in combination with tremelimumab determined by PD-L1 expression versus standard of care in patients with locally advanced or metastatic non-small cell lung cancer (ARCTIC). https://clinicaltrials.gov
26. Velu V, Titanji K, Zhu B et al. Enhancing SIV-specific immunity in vivo by PD-1 blockade. Nature 458(7235), 206-210 (2009)
27. Barber DL, Wherry EJ, Masopust D et al. Restoring function in exhausted CD8 T cells during chronic viral infection. Nature 439(7077), 682-687 (2006)
28. Blake SJP, Ching ALH, Kenna TJ et al. Blockade of PD-1/PD-L1 promotes adoptive T-cell immunotherapy in a tolerogenic environment. PLoS ONE doi:10.1371/ journal.ponew.0119483 (2015) (Epub ahead of print)
29. Rizvi NA, Shepherd FA, Antonia SJ. First-line monotherapy with nivolumab (Anti-PD-1; BMS 966558, ONO-4538) in advanced non-small cell lung cancer (NSCLC): safety, efficacy and correlation of outcomes with PD-L1 status. Ann. Oncol. 90(Suppl. 5S), Abstract 165 (2014)
30. Antonia SJ, Brahmer JR, Gettinger SN et al. Nivolumab (anti-PD-1; BMS-93655, ONO-4538) in combination with platinum-based doublet chemotherapy (PT-DC) in advanced non-small cell lung cancer (NSCLC). J. Clin. Oncol. 32(Suppl.), Abstract 8113 (2014)
31. Rizvi NA, Chow LQM, Borghaei H et al. Safety and response with nivolumab (anti-PD-1; BMS-936558, ONO-4538) plus erlotinib in patients (pts) with epidermal growth factor receptor mutant (EGFR MT) advanced NSCLC. J. Clin. Oncol. 32(Suppl.), Abstract 8022 (2014)
32. Antonia SJ, Gettinger SN, Chow LQM et al. Nivolumab (anti-PD-1; BMS-936558, ONO-4538) and ipilimumab in first-line NSCLC: interim Phase I results. J. Clin. Oncol. 32(Suppl.), Abstract 8023 (2014)
33. Rizvi NA, Mazieres J, Planchard D et al. Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small cell lung cancer (CheckMate 063): a Phase 2, single-arm trial. Lancet Oncol. 16, 257-265 (2015)
34. Gettinger SN, Horn L, Gandhi L et al. Overall survival and long-term safety of nivolumab (anti-programmed death 1 antibody, BMS-936558, ONO-4538) in patients with previously treated advanced non-small cell lung cancer. J. Clin. Oncol. 33(18), 2004-2012 (2015)
35. Topalian SL, Hodi FS, Brahmer JR et al. Safety, activity and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 366(26), 2443-2454 (2012)
36. Gettinger SN, Shepherd FA, Antonia SJ et al. First-line nivolumab (anti PD-1; BMS-936558, ONO-4538) monotherapy in advanced NSCLC: safety, efficacy and correlation of outcomes with PD-L1 status. J. Clin. Oncol. 32(Suppl.), Abstract 8024 (2014)
37. ClinicalTrials.gov: nivolumab after surgery and chemotherapy in treating patients with stage IB-IIIA non-small cell lung cancer (ANVIL). https://clinicaltrials.gov
38. ClinicalTrials.gov: study of nivolumab (BMS-936558) in combination with gemcitabine/cisplatin, pemetrexed/cisplatin, carboplatin/paclitaxel, bevacizumab maintenance, erlotinib, ipilimumab or as monotherapy in subjects with stage IIIB/IV non-small cell lung cancer (NSCLC) (CheckMate 012). https://clinicaltrials.gov
39. ClinicalTrials.gov: an open-label, randomized, Phase 3 trial of nivolumab versus investigator's choice chemotherapy as first-line therapy for stage IV or recurrent PD-L1+ non-small cell lung cancer (CheckMate 026). https://clinicaltrials.gov
40. ClinicalTrials.gov: an open-label, trial of nivolumab, or nivolumab plus ipilimumab, or nivolumab plus platinum-doublet chemotherapy versus platinum-doublet chemotherapy in subjects with stage IV non-small cell lung cancer (NSCLC) (CheckMate 227). https://clinicaltrials.gov
41. ClinicalTrials.gov: A safety trial of nivolumab (BMS-936558) in subjects with advanced or metastatic non-small cell lung cancer who have progressed during or after receiving at least one prior systemic regimen (CheckMate 153). https://clinicaltrials.gov
42. ClinicalTrials.gov: a study of pembrolizumab (MK-3475) in combination with chemotherapy or immunotherapy in participants with lung cancer (MK-3475-3021/KEYNOTE-021). https://clinicaltrials.gov
43. ClinicalTrials.gov: study of pembrolizumab (MK-3475) compared with platinum-based chemotherapies in participants with metastatic non-small cell lung cancer (MK-3475-3024/KEYNOTE-024). https://clinicaltrials.gov
44. ClinicalTrials.gov: study of MK-3475 (pembrolizumab) versus platinum-based chemotherapy for participants with PD-L1-positive advanced or metastatic non-small cell lung cancer (MK-3475-3042/ KEYNOTE-042). https://clinicaltrials.gov
45. ClinicalTrials.gov: pembrolizumab alone or in combination with ACP-196 in subjects with advanced non-small cell lung cancer (KEYNOTE166). https://clinicaltrials.gov
46. ClinicalTrials.gov: Phase II study of pembrolizumab after curative intent treatment for oligometastatic non-small cell lung cancer. https://clinicaltrials.gov
47. Garon EB, Gandhi L, Rizvi N et al. Antitumor activity of pembrolizumab (pembro; MK-3475) and correlation with programmed death ligand 1 (PD-L1) expression in a pooled analysis of patients (pts) with advanced non-small cell lung carcinoma (NSCLC). Ann. Oncol. 25(Suppl. 4), Abstract (2014)
48. Garon EB, Rizvi NA, Hui R et al. Pembrolizumab for the treatment of non-small cell lung cancer. N. Engl. J. Med. 372(21), 2018-2028 (2015)
49. Rizvi NA, Garon EB, Patnaik A et al. Safety and clinical activity of MK-3475 as initial therapy in patients with advanced non-small cell lung cancer (NSCLC). J. Clin. Oncol. 32(Suppl.), Abstract 8007 (2014)
50. Papadimitrakopoulou V, Patnaik A, Borghaei H et al. Pembrolizumab (pembro, MK-3475) plus platinum doublet chemotherapy (PDC) as front-line therapy for advanced non-small cell lung cancer (NSCLC): KEYNOTE-021 Cohorts A and C. J. Clin. Oncol. 33(Suppl.), Abstract 8031 (2015)
51. Patnaik A, Socinski MA, Gubens MA et al. Phase 1 study of pembrolizumab (pembro; MK-3475) plus ipilimumab (IPI) as second-line therapy for advanced non-small cell lung cancer (NSCLC): KEYNOTE-021 cohort D. J. Clin. Oncol. 33(Suppl.), Abstract 8011 (2015)
52. Herbst RS, Baas P, Kim DW et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet doi:10.1016/S0140-6736(15)01281-01287 (2015) (Epub ahead of print)
53. Herbst RS, Soria JC, Kowanetz M et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 515(7528), 563-567 (2014)
54. Spira AI, Park K, Mazieres J et al. Efficacy, safety and predictive biomarker results from a randomized Phase II study comparing MPDL3280A vs docetaxel in 2L/3L NSCLC (POPLAR). J. Clin. Oncol. 33(Suppl.), Abstract 8010 (2015)
55. Soria JC, Gettinger S, Gordon M et al. Biomarkers associated with clinical activity of PD-L1 blockade in non-small cell lung cancer (NSCLC) in a Phase I study of MPDL3280A. Ann. Oncol. 25(Suppl. 4), iv426-iv470 (2014)
56. ClinicalTrials.gov: a Phase 2 study of MPDL3280A (an engineered anti-PDL1 antibody) in patients with PD-L1 positive locally advanced or metastatic non-small cell lung cancer-"FIR". https://clinicaltrials.gov
57. ClinicalTrials.gov: a study of MPDL3280A compared with gemcitabine + cisplatin or carboplatin in patients with stage IV squamous non-small cell lung cancer [IMpower 111]. https://clinicaltrials.gov
58. ClinicalTrials.gov: a comparative study of MPDL3280A (anti-PDL1 antibody) with cisplatin or carboplatin + pemetrexed in patients with stage IV non-squamous non-small cell lung cancer (NSCLC) [IMpower 110]. https://clinicaltrials.gov
59. ClinicalTrials.gov: a Phase III study of MPDL3280A (anti-PD-L1) in combination with carboplatin + paclitaxel or carboplatin + Nab-paclitaxel compared with carboplatin + Nab-paclitaxel in patients with squamous non-small cell lung cancer (NSCLC) [IMpower 131]. https://clinicaltrials.gov
60. ClinicalTrials.gov: a Phase III study of MPDL3280A (anti-PD-L1 antibody) in combination with carboplatin + nab-paclitaxel in patients with non-squamous non-small cell lung cancer [IMpower130]. https://clinicaltrials.gov
61. ClinicalTrials.gov: a Phase III study of MPDL3280A (Anti-PD-L1 antibody) in combination with carboplatin + paclitaxel with or without bevacizumab in patients with stage IV non-squamous non-small cell lung cancer [IMpower150]. https://clinicaltrials.gov
62. ClinicalTrials.gov: a randomized Phase 3 study of MPDL3280A 9an engineered anti-PDL1 antibody) compared with docetaxel in patients with locally advanced or metastatic non-small cell lung cancer who have failed platinum therapy "OAK". https://clinicaltrials.gov
63. ClinicalTrials.gov: Phase III open label first line therapy study of MEDI 4736 with or without tremelimumab versus SOC in non-small cell lung cancer (NSCLC) (MYSTIC). https://clinicaltrials.gov
64. ClinicalTrials.gov: a global study to assess the effects of MEDI4736 following concurrent chemoradiation in patients with stage III unresectable non-small cell lung cancer (PACIFIC). https://clinicaltrials.gov
65. ClinicalTrials.gov: a global study to assess the effects of MEDI4736 in patients with locally advanced or metastatic non-small cell lung cancer (ATLANTIC). https://clinicaltrials.gov.show/NCT02087423
66. Brahmer JR, Rizvi NA, Lutzky J et al. Clinical activity and biomarkers of MEDI4736, an anti-PD-L1 antibody in patients with NSCLC. J. Clin. Oncol. 32(Suppl.), Abstract 8021 (2014)
67. Rizvi NA, Brahmer JR, Ignatius Ou SH et al. Safety and clinical activity of MEDI3476, an anti-programmed cell death-ligand 1 (PD-L1) antibody, in patients with non-small cell lung cancer (NSCLC). J. Clin. Oncol. 33(Suppl.), Abstract 8032 (2015)
68. Postow MA, Callahan MK, Wolchok JD. Immune checkpoint blockade in cancer therapy. J. Clin. Oncol. 33, 1974-1982 (2015)
69. Fecher LA, Agarwala SS, Hodi FS, Weber JS. Ipilimumab and its toxicities: a multidisciplinary approach. Oncologist 18, 733-743 (2013)
70. Wolchok JD, Weber JS, Maio M et al. Four-year survival rates for patients with metastatic melanoma who received ipilimumab in Phase II clinical trials. Ann. Oncol. 24, 2174-2180 (2013)
71. Postow MA, Callahan MK, Barker CA et al. Immunologic correlates of the abscopal effect in a patient with melanoma. N. Engl. J. Med. 366(10), 925-931 (2012)
72. Hellman MD, Creedan BC, Woo K et al. Smoking history and response to nivolumab in patients with advanced NSCLCs. Ann. Oncol. 25(Suppl.), Abstract 1229PD (2014)
73. Champiat S, Ferre C, Lebel-Binay S, Eggermont A, Soria JC. Exomics and immunogenics. Oncoimmunology 3, e27817-1-6 (2014)
74. Lawrence MS, Stoijanov P, Polak P et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature 499, 214-218 (2013)
75. Socinski MA. Incorporating immunotherapy into the treatment of non-small cell lung cancer: practical guidance for the clinic. Semin. Oncol. 42(Suppl. 2), S19-S28 (2015)
76. Pao W, Miller V. Epidermal growth factor receptor mutations, small molecule kinase inhibitors and non-small cell lung cancer: current knowledge and future directions. J. Clin. Oncol. 23, 2556-2568 (2005)
77. Gao G, Ren S, Li A et al. Epidermal growth factor receptor-tyrosine kinase inhibitor therapy is effective as first-line treatment of advanced non-small cell lung cancer with mutated EGFR: a meta-analysis from six Phase III randomised controlled trials. Int. J. Cancer 131, E822-E829 (2012)
78. Kerr KM, Tsao MS, Nicholson AG. Programmed death-ligand 1 immunohistochemistry in lung cancer. In what state is this art? J. Thor. Oncol. 10, 985-989 (2015)
79. Mok TS, Loong HH. Are we ready for immune checkpoint inhibitors for advanced non-small cell lung cancer? Lancet doi:10.1016/S0140-6736(15)01308-01302 (2015) (Epub ahead of print)
80. Hiraoka K, Miyamoto M, Cho Y et al. Concurrent infiltration by CD8+ T cells and CD4+ T cells is a favourable prognostic factor in non-small cell lung carcinoma. Br. J. Cancer 94, 275-280 (2006)
81. Snyder A, Makarov V, Merghoub T et al. genetic basis for clinical response to CTLA-4 blockade in melanoma. N. Engl. J. Med. 371(23), 2189-2199 (2014)
82. Rizvi NA, Hellman MD, Snyder A et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 348(6230), 124-128 (2015)
83. Le DT, Uram JN, Wang H et al. PD-1 blockade in tumors with mismatch-repair deficiency. N. Engl. J. Med. 372(26), 2509-2520 (2015)
84. Pilotto S, Molina-Vila MA, Karachaliou N et al. Integrating the molecular background of targeted therapy and immunotherapy in lung cancer: a way to explore the impact of mutational landscape on tumor immunogenicity. Transl. Lung Cancer Res. 4(6), 721-727 (2015)
85. WHO handbook for reporting results of cancer treatment. Geneva (Switzerland): World Health Organization Offset Publication No. 48 (1979). http://apps.who.int/iris/handle/10665/37200
86. Therase P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumors. J. Natl Cancer Inst. 92, 205-216 (2000)
87. Eisenhauer EA, Therase P, Bogaerts J et al. New response evaluation criteria in solid tumours; revised RECIST guideline (version 1.1). Eur. J. Cancer 45(2), 228-247 (2009)
88. Wolchok JD, Hoos A, O'Day S et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin. Cancer Res. 15(23), 7412-7420 (2009)
89. Hodi FS, Sznol M, Kulger HM et al. Long-term survival of ipilimumab-naïve patients (pts) with advanced melanoma (MEL) treated with nivolumab (anti-PD-1, BMS-936558, ONO-4538) in a Phase I trial. J. Clin. Oncol. 32(Suppl.), Abstract 9002 (2014)
90. Chiou VL, Burotto M. Pseudoprogression and immune-related response in solid tumors. J. Clin. Oncol. 33, 3541-3543 (2015)
91. Hoos A. Evolution of end points for cancer immunotherapy trials. Ann. Oncol. 23(Suppl. 8), vii47-vii52 (2012)
92. Hodi FS, O'Day SJ, McDermott DF et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363, 711-723 (2010)
93. Ettinger DS, Wood DE, Akerley W et al. NCCN Guidelines Insights: non-small cell lung cancer, version 4.2016. J. Natl Compr. Canc. Netw. 14(3), 255-264 (2016)